AUS Edition 
NZ Edition 
UK Edition 
CA Edition 
USA Edition 
FRA Edition 
GER Edition 
ESP Edition 
ITA Edition 
NLD Edition 
PRT Edition 
SWE Edition 
GRC Edition 
IND Edition 
POL Edition 
BRA Edition 
ZAF Edition 
RUS Edition 
CHN Edition 
UAE Edition 
⚠
✓
Edgewise Therapeutics Inc (NASDAQ:EWTX)
14.13 USD
-0.340 2.350%Sponsored Reports
Loading...
| Previous Close (in USD) | 14.47 |
|---|---|
| Change | -0.340 2.350% |
| 52 W H/L (in USD) | 21.600/5.120 |
| EBITDA (in USD) | -121.577M |
| PE Ratio | -- |
| Volume | 200703 |
| Diluted Eps TTM | -1.54 |
| Total Assets (in USD) | 340.035M |
|---|---|
| Total Liabilities (in USD) | 21.205M |
| Revenue TTM (in USD) | -- |
| Cash (in USD) | 86.097M |
| Market Cap (in USD) | 1,598.054 M |
| Revenue Per Share TTM | -- |
| Gross Profit TTM (in USD) | -- |
Summary
Income Statement
Balance Sheet
Change in Cash
Operating Cash
Edgewise Therapeutics Inc
Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.
Employees: 92
Key Executives
| Sr. No. | Name | Title | Year Born |
|---|---|---|---|
| 1. | Dr. Kevin Koch Ph.D. | Pres, CEO & Director | 1960 |
| 2. | Dr. Badreddin Edris Ph.D. | Co-Founder & Independent Director | 1987 |
| 3. | Dr. Behrad Derakhshan Ph.D. | Chief Bus. Officer | 1980 |
| 4. | Dr. Joanne M. Donovan M.D., Ph.D. | Chief Medical Officer | 1957 |
| 5. | Dr. Alan J. Russell Ph.D. | Co-Founder, Chief Scientific Officer & Director | 1970 |
| 6. | Mr. R. Michael Carruthers | Chief Financial Officer | 1958 |
| 7. | Mr. John R. Moore | Gen. Counsel | 1964 |
| 8. | Dr. Peter A. Thompson FACP, M.D. | Co-Founder & Independent Chairman | 1960 |
| 9. | Dr. Kevin Koch Ph.D. | President, CEO & Director | 1960 |
| 10. | Dr. Badreddin Edris Ph.D. | Co-Founder & Independent Director | 1988 |
Peers
Sector: Healthcare
Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE(x) | Forward PE(x) | Price Sales TTM(x) | Price to Book Value(x) | Enterprise Value to Revenue(x) | Enterprise Value to EBITDA(x) |
|
NVO
Novo Nordisk A/S |
-0.365 0.493% | 73.84 | 41.580 | 31.153 | 2.134 | 32.989 | 2.113 | 4.700 |
|
NONOF
Novo Nordisk A/S |
-1.320 1.776% | 73 | 41.060 | 31.250 | 2.078 | 33.111 | 2.113 | 4.700 |
|
VRTX
Vertex Pharmaceuticals Inc |
-9.585 2.138% | 451.26 | 29.670 | 24.331 | 10.385 | 5.832 | 9.334 | 20.004 |
|
REGN
Regeneron Pharmaceuticals Inc |
-3.910 0.761% | 521.05 | 29.070 | 20.121 | 7.570 | 3.823 | 6.950 | 19.423 |
Income Statement
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 |
|---|---|---|---|---|
| Income Before Tax | -19.415M | -42.813M | -17.123M | -9.705M |
| Minority Interest | - | - | - | - |
| Net Income | -15.397M | -42.139M | -17.054M | -9.486M |
| Selling General Administrative | 5.467M | 11.026M | 2.209M | 1.3M |
| Gross Profit | - | - | - | - |
| Reconciled Depreciation | 0.538M | 0.272M | 0.185M | 0.123M |
| Ebit | -22.617M | -43.487M | -17.192M | -9.924M |
| Ebitda | -22.079M | -43.215M | -17.007M | -9.801M |
| Depreciation And Amortization | 0.538M | 0.272M | 0.185M | 0.123M |
| Operating Income | -22.079M | -43.215M | -17.192M | -9.924M |
| Other Operating Expenses | 22.079M | 43.215M | 17.192M | 9.924M |
| Interest Expense | 4.018M | 0.272M | 0.069M | 0M |
| Tax Provision | - | - | - | - |
| Interest Income | 4.018M | 0.402M | 0.069M | 0.219M |
| Net Interest Income | 4.018M | 0.402M | 0.069M | 0.219M |
| Income Tax Expense | -4.018M | -0.674M | -0.069M | -0.219M |
| Total Revenue | 0M | 0M | 0M | 0M |
| Total Operating Expenses | 22.079M | 43.215M | 17.192M | 9.924M |
| Cost Of Revenue | - | - | - | - |
| Total Other Income Expense Net | 2.664M | 0.402M | 0.069M | 0.219M |
| Net Income From Continuing Ops | -67.64M | -42.813M | -17.123M | -9.705M |
| Net Income Applicable To Common Shares | -67.64M | -42.813M | -17.123M | -9.705M |
Balance Sheet
(Currency in USD)| Breakdown | 31-12-2023 | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 |
|---|---|---|---|---|---|
| Total Assets | 340.035M | 367.101M | 285.233M | 131.136M | 24.541M |
| Intangible Assets | - | - | - | - | - |
| Other Current Assets | 8.604M | 5.052M | 2.984M | 0.551M | 0.39M |
| Total Liab | 21.205M | 20.385M | 10.85M | 164.556M | 41.394M |
| Total Stockholder Equity | 318.83M | 346.716M | 274.383M | -33.42M | -16.853M |
| Other Current Liab | 11.766M | 9.872M | 6.678M | 2.762M | 0.465M |
| Common Stock | 0.007M | 0.006M | 0.005M | - | - |
| Capital Stock | 0.007M | 0.006M | 0.005M | 0M | 0M |
| Retained Earnings | -244.763M | -144.6M | -76.96M | -34.147M | -17.024M |
| Good Will | - | - | - | - | - |
| Other Assets | - | 0.251M | 0.548M | 0.975M | - |
| Cash | 86.097M | 351.947M | 280.789M | 104.916M | 23.653M |
| Cash And Equivalents | - | - | - | - | - |
| Total Current Liabilities | 16.771M | 16.585M | 10.521M | 4.342M | 1.132M |
| Current Deferred Revenue | - | - | - | - | - |
| Net Debt | -80.683M | -347.539M | -280.789M | -104.916M | -23.653M |
| Short Term Debt | 0.98M | 0.608M | - | - | - |
| Short Long Term Debt | - | - | - | - | - |
| Short Long Term Debt Total | 5.414M | 4.408M | - | - | - |
| Other Stockholder Equity | 563.487M | 492.665M | 66.619M | 0.727M | 0.171M |
| Property Plant Equipment | - | 8.533M | 0.912M | 0.516M | 0.498M |
| Total Current Assets | 326.997M | 351.947M | 280.789M | 129.645M | 24.043M |
| Long Term Investments | - | - | - | - | - |
| Short Term Investments | 232.296M | 329.954M | 265.223M | 24.178M | 0M |
| Net Receivables | - | 0.251M | 0.548M | - | - |
| Long Term Debt | - | - | - | - | - |
| Inventory | - | - | - | - | - |
| Accounts Payable | 4.025M | 6.105M | 3.843M | 1.58M | 0.667M |
| Accumulated Other Comprehensive Income | 0.099M | -1.355M | -0.514M | -0.43M | -0.245M |
| Non Currrent Assets Other | 0.348M | 5.303M | 3.532M | 0.975M | - |
| Non Current Assets Total | 13.038M | 15.154M | 4.444M | 1.491M | 0.498M |
| Capital Lease Obligations | 5.414M | 4.408M | - | - | - |
| Long Term Debt Total | - | - | - | - | - |
Cash Flow
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 |
|---|---|---|---|---|
| Investments | -70.577M | -241.559M | -24.178M | -24.178M |
| Total Cashflows From Investing Activities | -70.577M | -242.227M | -24.381M | -0.18M |
| Total Cash From Financing Activities | 129.639M | 186.384M | 120.278M | 24.8M |
| Net Income | -67.64M | -42.813M | -17.123M | -9.705M |
| Change In Cash | 6.427M | -89.35M | 81.263M | 15.449M |
| Begin Period Cash Flow | 15.566M | 104.916M | 23.653M | 8.204M |
| End Period Cash Flow | 21.993M | 15.566M | 104.916M | 23.653M |
| Total Cash From Operating Activities | -52.635M | -33.507M | -14.634M | -9.171M |
| Depreciation | 0.538M | 0.272M | 0.185M | 0.123M |
| Other Cashflows From Investing Activities | - | - | - | - |
| Dividends Paid | - | - | - | - |
| Change To Inventory | - | - | - | - |
| Sale Purchase Of Stock | 129.89M | 186.384M | - | - |
| Other Cashflows From Financing Activities | 0.474M | 0.236M | -24.381M | -0.18M |
| Capital Expenditures | 5.546M | 0.668M | 0.203M | 0.18M |
| Change In Working Capital | 4.086M | 4.63M | 1.95M | 0.334M |
| Other Non Cash Items | -0.543M | -228.945M | -100.442M | - |
| Free Cash Flow | -58.181M | -34.175M | -14.837M | -9.351M |
Funds
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Vanguard Total Stock Mkt Idx Inv | 1 year ago | 2547279 |
| 2. | Fidelity Small Cap Growth | 1 year ago | 1357058 |
| 3. | iShares Russell 2000 ETF | 1 year ago | 1333596 |
| 4. | Vanguard Institutional Extnd Mkt Idx Tr | 1 year ago | 982953 |
| 5. | Fidelity Series Small Cap Opps | 1 year ago | 744855 |
| 6. | iShares Russell 2000 Value ETF | 1 year ago | 531492 |
| 7. | Fidelity Small Cap Growth K6 | 1 year ago | 507989 |
| 8. | Fidelity Select Health Care | 1 year ago | 500000 |
| 9. | Fidelity Select Biotechnology | 1 year ago | 474685 |
| 10. | iShares Biotechnology ETF | 1 year ago | 443988 |
| 11. | Fidelity Small Cap Index | 1 year ago | 437368 |
| 12. | Fidelity Select Pharmaceuticals Port | 1 year ago | 436300 |
| 13. | Strategic Advisers Fidelity US TtlStk | 1 year ago | 433950 |
| 14. | Fidelity Stock Selector Small Cap | 1 year ago | 399545 |
| 15. | American Century Small Cap Growth Inv | 1 year ago | 394255 |
| 16. | American Century U.S. Small Cap Growth | 1 year ago | 394255 |
| 17. | Fidelity Extended Market Index | 1 year ago | 367065 |
| 18. | State St Russell Sm/Mid Cp® Indx NL Cl C | 1 year ago | 351101 |
| 19. | Candriam Eqs L Biotech C USD Cap | 1 year ago | 329000 |
| 20. | Fidelity Advisor Biotechnology I | 1 year ago | 315900 |
Institutions
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Orbimed Advisors, LLC | 1 year ago | 15021721 |
| 2. | FMR Inc | 1 year ago | 6492513 |
| 3. | Baker Bros Advisors LP | 1 year ago | 5840059 |
| 4. | Vanguard Group Inc | 1 year ago | 4017433 |
| 5. | Viking Global Investors LP | 1 year ago | 3339146 |
| 6. | BlackRock Inc | 1 year ago | 3307110 |
| 7. | Cormorant Asset Management, LLC | 1 year ago | 3006534 |
| 8. | Perceptive Advisors LLC | 1 year ago | 2319646 |
| 9. | HHG PLC | 1 year ago | 1805312 |
| 10. | Goldman Sachs Group Inc | 1 year ago | 1763792 |
| 11. | New Leaf Venture Partners, L.L.C. | 1 year ago | 1553661 |
| 12. | Driehaus Capital Management LLC | 1 year ago | 1267819 |
| 13. | EcoR1 Capital, LLC | 1 year ago | 1250385 |
| 14. | Geode Capital Management, LLC | 1 year ago | 947046 |
| 15. | State Street Corporation | 1 year ago | 892709 |
| 16. | Barclays PLC | 1 year ago | 778916 |
| 17. | Opaleye Management Inc | 1 year ago | 665000 |
| 18. | Parkman Healthcare Partners LLC | 1 year ago | 653653 |
| 19. | Granahan Investment Management Inc.. | 1 year ago | 608012 |
| 20. | American Century Companies Inc | 1 year ago | 559334 |
Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peertrades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
Sponsored Articles
Loading...
Related Articles
Loading...